These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

45 related articles for article (PubMed ID: 20415593)

  • 1. Recombinant human follicular stimulating hormone and recombinant human luteinizing hormone in a 2:1 ratio combination. Pharmacological characteristics and clinical applications.
    Bosch E
    Expert Opin Biol Ther; 2010 Jun; 10(6):1001-9. PubMed ID: 20415593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of recombinant LH treatment on folliculogenesis and responsiveness to FSH stimulation.
    Durnerin CI; Erb K; Fleming R; Hillier H; Hillier SG; Howles CM; Hugues JN; Lass A; Lyall H; Rasmussen P; Thong J; Traynor I; Westergaard L; Yates R;
    Hum Reprod; 2008 Feb; 23(2):421-6. PubMed ID: 18084048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of recombinant human LH (lutropin alfa) in the late stimulation phase of assisted reproduction cycles: a double-blind, randomized, prospective study.
    Tarlatzis B; Tavmergen E; Szamatowicz M; Barash A; Amit A; Levitas E; Shoham Z
    Hum Reprod; 2006 Jan; 21(1):90-4. PubMed ID: 16172149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Pergoveris in Assisted Reproductive Technology--ESPART: rationale and design of a randomised controlled trial in poor ovarian responders undergoing IVF/ICSI treatment.
    Humaidan P; Schertz J; Fischer R
    BMJ Open; 2015 Jul; 5(7):e008297. PubMed ID: 26141305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical effects of ovulation induction with recombinant follicle-stimulating hormone supplemented with recombinant luteinizing hormone or low-dose recombinant human chorionic gonadotropin in the midfollicular phase in microdose cycles in poor responders.
    Berkkanoglu M; Isikoglu M; Aydin D; Ozgur K
    Fertil Steril; 2007 Sep; 88(3):665-9. PubMed ID: 17292895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive factors and a corresponding treatment algorithm for controlled ovarian stimulation in patients treated with recombinant human follicle stimulating hormone (follitropin alfa) during assisted reproduction technology (ART) procedures. An analysis of 1378 patients.
    Howles CM; Saunders H; Alam V; Engrand P;
    Curr Med Res Opin; 2006 May; 22(5):907-18. PubMed ID: 16709312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Follicular phase serum levels of luteinizing hormone do not influence delivery rates in in vitro fertilization cycles down-regulated with a gonadotropin-releasing hormone agonist and stimulated with recombinant follicle-stimulating hormone.
    Cabrera RA; Stadtmauer L; Mayer JF; Gibbons WE; Oehninger S
    Fertil Steril; 2005 Jan; 83(1):42-8. PubMed ID: 15652885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant LH (lutropin alfa) for the treatment of hypogonadotrophic women with profound LH deficiency: a randomized, double-blind, placebo-controlled, proof-of-efficacy study.
    Shoham Z; Smith H; Yeko T; O'Brien F; Hemsey G; O'Dea L
    Clin Endocrinol (Oxf); 2008 Sep; 69(3):471-8. PubMed ID: 18485121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lower apoptosis rate in human cumulus cells after administration of recombinant luteinizing hormone to women undergoing ovarian stimulation for in vitro fertilization procedures.
    Ruvolo G; Bosco L; Pane A; Morici G; Cittadini E; Roccheri MC
    Fertil Steril; 2007 Mar; 87(3):542-6. PubMed ID: 17126339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of recombinant human luteinising hormone (r-hLH) and human menopausal gonadotropin (hMG) in assisted reproductive technology.
    Baer G; Loumaye E
    Curr Med Res Opin; 2003; 19(2):83-8. PubMed ID: 12740151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant human luteinizing hormone, lutropin alfa, for the induction of follicular development and pregnancy in profoundly gonadotrophin-deficient women.
    Kaufmann R; Dunn R; Vaughn T; Hughes G; O'Brien F; Hemsey G; Thomson B; O'Dea LS
    Clin Endocrinol (Oxf); 2007 Oct; 67(4):563-9. PubMed ID: 17692110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical efficacy of highly purified urinary FSH versus recombinant FSH in volunteers undergoing controlled ovarian stimulation for in vitro fertilization: a randomized, multicenter, investigator-blind trial.
    Baker VL; Fujimoto VY; Kettel LM; Adamson GD; Hoehler F; Jones CE; Soules MR
    Fertil Steril; 2009 Apr; 91(4):1005-11. PubMed ID: 18367182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results with early follicular phase recombinant luteinizing hormone supplementation during stimulation for in vitro fertilization.
    Kovacs P; Kovats T; Kaali SG
    Fertil Steril; 2010 Feb; 93(2):475-9. PubMed ID: 19200991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A combined analysis of data to identify predictive factors for spermatogenesis in men with hypogonadotropic hypogonadism treated with recombinant human follicle-stimulating hormone and human chorionic gonadotropin.
    Warne DW; Decosterd G; Okada H; Yano Y; Koide N; Howles CM
    Fertil Steril; 2009 Aug; 92(2):594-604. PubMed ID: 18930225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in recombinant DNA technology: corifollitropin alfa, a hybrid molecule with sustained follicle-stimulating activity and reduced injection frequency.
    Fauser BC; Mannaerts BM; Devroey P; Leader A; Boime I; Baird DT
    Hum Reprod Update; 2009; 15(3):309-21. PubMed ID: 19182099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FSH and LH together in ovarian stimulation.
    Levi-Setti PE; Cavagna M; Baggiani A; Zannoni E; Colombo GV; Liprandi V
    Eur J Obstet Gynecol Reprod Biol; 2004 Jul; 115 Suppl 1():S34-9. PubMed ID: 15196714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant human LH supplementation versus recombinant human FSH (rFSH) step-up protocol during controlled ovarian stimulation in normogonadotrophic women with initial inadequate ovarian response to rFSH. A multicentre, prospective, randomized controlled trial.
    De Placido G; Alviggi C; Perino A; Strina I; Lisi F; Fasolino A; De Palo R; Ranieri A; Colacurci N; Mollo A;
    Hum Reprod; 2005 Feb; 20(2):390-6. PubMed ID: 15576390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Follicular fluid hormone concentrations after ovarian stimulation using gonadotropin preparations with different FSH/LH ratios. II. Comparison of hMG and recombinant FSH.
    Duijkers IJ; Willemsen WN; Hollanders HM; Hamilton CJ; Thomas CM; Vemer HM
    Int J Fertil Womens Med; 1997; 42(6):431-5. PubMed ID: 9459089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical use of recombinant gonadotropins (FSH, LH, hCG)].
    Antoine JM; Loumaye E; Alvarez S; Merviel P; Cornet D; Mandelbaum J; Salat-Baroux J
    Contracept Fertil Sex; 1997 Feb; 25(2):141-6. PubMed ID: 9116774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ovarian response and pregnancy outcome in poor-responder women: a randomized controlled trial on the effect of luteinizing hormone supplementation on in vitro fertilization cycles.
    Barrenetxea G; Agirregoikoa JA; Jiménez MR; de Larruzea AL; Ganzabal T; Carbonero K
    Fertil Steril; 2008 Mar; 89(3):546-53. PubMed ID: 17531989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.